No Psychological Harm in Knowing Alzheimer's Risk
Individuals who were told they didn't have elevated amyloid beta had reductions in all emotional parameters assessed compared to baseline, while peers who were told they did have amyloid beta deposits experienced a modest decrease in anxiety and no change in depression.
'We observed no significant harm after disclosure. However, motivation to adopt lifestyle changes decreased after disclosing both elevated and nonelevated amyloid beta status and should be targeted,' the study team reported.
'The results highlight how easily people lose motivation to make lifestyle changes aimed at maintaining cognitive health. Strategies to sustain these healthy behaviors are crucial,' first author Sapir Golan Shekhtman, PhD candidate, The Joseph Sagol Neuroscience Center, Sheba Medical Center in Ramat Gan, Israel, said in a statement.
The study was published online on May 7 in Alzheimer's & Dementia.
Important Topic, Limited Data
Amyloid beta deposition, an early hallmark of AD, is detectable through PET imaging years before cognitive symptoms manifest.
With the increasing use of this and other AD biomarkers for early diagnosis and treatment eligibility, there is a need to better understand how cognitively normal individuals emotionally react to learning their biomarker status.
To investigate, Shekhtman and colleagues surveyed 199 at-risk, but cognitively normal, adults before and 6 months after they underwent amyloid PET scans to determine amyloid beta status. Most were enrolled in observational trials.
Disclosure of nonelevated amyloid beta was associated with a significant decrease in anxiety and depression (P < .001), as well as subjective memory complaints (P < .001), suggesting a feeling of relief and decreased worry when ruling out the presence of AD pathology, the researchers said.
Disclosure of elevated amyloid beta status was associated with no change in depression or memory complaints and, counter intuitively, with a modest decrease in anxiety (P = .026).
The authors cautioned that the elevated amyloid beta group only included 21 individuals, which is 'too small to draw definitive conclusions.' The individuals with elevated amyloid beta were also older than those with nonelevated amyloid beta (median, 81 years vs 63 years).
While both groups expressed strong motivation to implement lifestyle changes at baseline, after disclosure, a significant decrease in reported motivation to pursue lifestyle changes was observed in both groups, although to a lesser extent in the elevated amyloid beta group.
In the nonelevated amyloid beta group, this may be attributed to the relief of not having AD pathology, the authors suggested.
The causes for decreased motivation are less understood in the elevated amyloid beta group. However, it is concerning as maintaining a healthy, active lifestyle is a key recommendation for the prevention of AD, they added.
Summing up, the researchers said the findings are in-line with previous studies showing that amyloid beta status disclosure has a low risk for psychological harm both in elevated and nonelevated amyloid beta levels.
Looking ahead, they said research is needed to identify populations with elevated psychological vulnerability and develop personalized communication strategies.
'Mechanisms behind decreased motivation for lifestyle changes after disclosure should be further explored and targeted,' they added.
Funding for this research was provided by the National Institute on Aging and the Alzheimer's Association. The authors declared having no relevant disclosures.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vogue
an hour ago
- Vogue
The Inaugural Franca Fund Gala Will Take Place This November in Doha
There is a new addition to the 2025 gala calendar: This November in Doha, filmmaker and photographer Francesco Carrozzini, Her Excellency Sheikha Al Mayassa bint Hamad Al-Thani, and Anna Wintour, global editorial director of Vogue and chief content officer of Condé Nast, will host the inaugural Franca Fund Gala—a fundraiser to support ongoing preventative genomics research in honor of Carrozzini's late mother, longtime Italian Vogue editor Franca Sozzani. 'The bond I had with my mom—and her being a single mother for most of her life and then going so early—really made me want to do something to remember her,' Carrozzini tells Vogue, adding that his mother's diagnosis of a rare lung cancer led him to the work of Harvard medical geneticist Dr. Robert E. Green, in hopes of finding her a cure. That Sozzani's illness was too advanced to be successfully treated, and she died in late 2016, prompted Carrozzini to establish The Franca Fund for Preventive Genomics, alongside Green and artist and investor D.A. Wallch. The initiative supports genetic research to identify, treat, and prevent a myriad of diseases—from minor ailments to life-threatening illnesses. Since launching in 2018 at Harvard Medical School and Mass General Brigham, the fund has raised money through the exhibition and sale of pieces from Sozzani's wardrobe; a Zara collection of tees and sweatshirts featuring Peter Lindbergh photos; and an awards dinner that has honored Julianne Moore, Salma Hayek, and Iman. Still, Carrozzini has often found himself thinking, 'this is not enough, we need something bigger,' he says. Enter the Franca Fund Gala, which was conceived in collaboration with Sheikha Al Mayassa. 'I was looking to do something with someone who understood my mother's values and what she did for the arts and for fashion,' Carrozzini says, noting that before her death, Sozzani befriended Sheikha Al Mayassa through those shared interests. The chairperson of Qatar Museums and co-chair of Fashion Trust Arabia, Sheikha Al Mayassa 'kindly offered to host' the Franca Fund Gala, Carrozzini adds. The evening will be held in collaboration with the Qatari cultural center M7, a hub for innovation and entrepreneurship across design, fashion, and technology. Additional details regarding the guest list, venue, dress code, and entertainment are forthcoming, but the mission, Carrozzini says, is already clear: 'To promote research, and to honor someone who so many people thought was special.'
Yahoo
an hour ago
- Yahoo
ARC and Revealense unite to develop AI neurological diagnostic
The Accelerate, Redesign, and Collaborate (ARC) innovation centre at Israel's Sheba Medical Center has partnered with Revealense to develop an AI-based diagnostic for evaluating neurological conditions. Underpinned by Revealense's AI behavioural analysis platform, the diagnostic will take the form of a webcam for at-home evaluation. The tool will assess an individual's condition by factoring in potential environmental influences, monitoring changes over time, and recommending personalised care plans for each user. Sheba Medical Center's child development centre director, Dr Omer Bar Yosef, will serve as project lead. According to the parties, the finalised product will achieve clinically validated diagnoses across a wide range of neurological, cognitive, and developmental conditions. However, the project will initially establish diagnostic protocols for autism spectrum disorder (ASD), ADHD, which research indicates has a high comorbidity rate with ASD, and related conditions. Revealense CEO Dov Donin claims the collaboration could lead to a 'profound shift' in how neurological disorders are understood, diagnosed, and treated. According to Donin, a combination of computational models, psychophysiological measurements, and real-time monitoring holds the potential to 'elevate the entire diagnostics landscape'. The current ASD diagnostic landscape The DSM-5 criteria, a standardised system for classifying a range of brain-related conditions, have long been viewed as the gold standard for diagnosing ASD. However, research indicates that challenges in assessment access result in high rates of underdiagnosis. A 2023 population-level study estimated that 750,000 UK adults may be undiagnosed with ASD while research from the US suggests that up to two million adults may be undiagnosed. Sheba Impact CEO Avner Halperin commented: 'This partnership will enable a faster neurological diagnostic process with increased accuracy and reliability, while improving accessibility by moving from the clinic to home.' ARC and Revealense's partnership continues the growing trend for AI-based ASD diagnostics, yet the field currently remains small. In 2024, Cognoa's AI-based child autism diagnostic became available as a covered benefit under Wyoming Medicaid. The device, which uses data collection and AI to aid in the clinical evaluation of ASD, gained de novo clearance from the FDA in 2021 for ASD diagnosis in children aged 18 months to six years. In January 2025, Schweitzer Engineering Laboratories (SEL) announced plans to expand into the medical device sector to produce a diagnostic for early ASD. The National Institutes of Health (NIH) and the US Centers for Medicare & Medicaid Services (CMS) announced plans in May to develop a real-world data platform in the US that some observers said would amount to a registry for individuals with ASD. US Health Secretary Robert F Kennedy, Jr (RFK Jr) claimed the initiative would help determine the 'root cause' of ASD 'by September 2025. RFK Jr, who has previously shared the widely debunked claim that vaccines cause autism, faced consternation by the wider autism community. A petition was filed against the plans, branding the mooted platform a "slippery slope to eugenics". "ARC and Revealense unite to develop AI neurological diagnostic" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Medscape
3 hours ago
- Medscape
Alzheimer's Med Continues to Deliver Benefit at 3 Years
Data from the TRAILBLAZER-ALZ 2 long-term extension (LTE) study demonstrated that donanemab (Kisunla, Eli Lilly and Company) continues to deliver meaningful benefits that increase over 3 years, especially when started early, with a manageable safety profile. 'There was a 27% reduced risk of progression if you were started initially in the trial versus delayed in the trial,' reported study investigator Mark Mintun, MD, group vice president of Neuroscience Research & Development at Eli Lilly and Company. The core TRAILBLAZER-ALZ 2 study results were presented 2 years ago at the Alzheimer's Association International Conference (AAIC) and simultaneously published in JAMA . The most recent results were presented on July 30 at the AAIC 2025. Ongoing Disease-Modifying Effects Participants in the core study who completed the 76-week placebo-controlled period were eligible to continue in the LTE period, lasting an additional 78 weeks. The LTE study included 550 'early-start' participants who initiated donanemab in the core study and either continued it or were switched to placebo after meeting predefined amyloid clearance thresholds. These participants were followed in the LTE period to assess the long-term safety and durability of treatment effects. The LTE study also included 657 'delayed-start' participants who received placebo in the core study and switched to donanemab at the start of the LTE period in a blinded manner to evaluate delayed treatment outcomes. Compared with a matched, untreated external cohort from the Alzheimer's Disease Neuroimaging Initiative, patients initially treated with donanemab in the core study had a reduction in cognitive decline at 18 months of 0.6 points on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) — and this benefit grew to 1.2 points at 36 months. 'What we saw was that the benefits continued to grow and ended up essentially doubling with a benefit of 1.2 CDR sum of boxes versus the control arm at the end of the 3-year trial,' Mintun told conference attendees. Nearly half of patients in the delayed donanemab start group had progressed to moderate Alzheimer's disease (AD) by the time they started treatment in the LTE period. Despite this, they still achieved a 0.8 CDR-SB benefit after 3 years. Compared with delayed start, early start reduced the risk for progression on the CDR global scale by 27%, Mintun noted. Amyloid clearance was consistent across groups. More than three quarters of patients treated with donanemab reached amyloid clearance within 76 weeks of starting treatment. Long-term follow-up showed slow reaccumulation of amyloid of about 2.5 CL/y. No new safety signals were observed in the LTE period. Safety outcomes were similar across the early- and delayed-start groups. Amyloid-related imaging abnormalities (ARIA) and infusion-related events occurred at comparable rates whether treatment was started early or delayed. Encouraging Confirmation Reached for comment, Eric Reiman, MD, executive director at the Banner Alzheimer's Institute, Phoenix, said it's 'encouraging to see confirmation of the view that many in the field have is that these treatments will continue to show a greater benefit when followed over longer periods of time, and that starting earlier is likely to be better, as we would have expected.' The observed pattern of continued benefit over time 'supports the concept of a disease-modifying treatment, rather than purely a symptomatic treatment,' Reiman told Medscape Medical News . Also providing perspective, Rebecca M. Edelmayer, PhD, Alzheimer's Association vice president of Scientific Engagement, said a key message is to 'diagnose and treat Alzheimer's disease early to get the most benefit.' 'Patients in the study who were treated in earlier stages of disease progression exhibited greater and increasing benefits compared to those with delayed treatment or no treatment. Patients at earlier disease stages and younger patients experienced more pronounced benefits,' said Edelmayer. She also noted that stopping donanemab once the patient achieves amyloid clearance is a 'feasible treatment strategy [and] may reduce patient and healthcare provider/system burden. Close monitoring and ongoing surveillance remain essential, including MRI monitoring for ARIA, especially in APOE-ε4 carriers. New titration guidelines and FDA guidance designed to reduce ARIA risk improve the safety profile of the treatment,' Edelmayer said. Edelmayer also emphasized the importance of collecting real-world data outside of what can typically be learned through clinical trials. 'The Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) collects real-world data from patients receiving care across a variety of clinical settings who are being evaluated for or treated with new, approved Alzheimer's treatments. The evidence gathered will be used to advance research, improve health equity and patient care, and inform Alzheimer's and other dementia treatment practices,' Edelmayer said. 'The data gathered can be used by professional and nonprofessional care providers, diagnostic companies, EHR companies, private and public funders, researchers, life sciences companies, payors, public health, and government and regulatory policymakers to improve care,' she added. ALZ-NET is now enrolling clinical sites across the country.
